DNA Methylation Biomarkers for PMDD and PMD Risk Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for premenstrual dysphoric disorder (PMDD) and perimenopausal depression (PMD) are inaccurate and complex, leading to delayed and inadequate treatment, which can impact quality of life and increase the risk of dementia.
Innovation Solution
The use of DNA methylation biomarkers, specifically HP1BP3, TTC9B, and MS4A7, to measure differential methylation levels and white blood cell ratios in nucleic acid samples to diagnose and predict PMDD and PMD, and determine responsiveness to selective serotonin reuptake inhibitors (SSRIs).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If DNA methylation biomarkers are used for diagnosis, then diagnostic accuracy is improved, but diagnostic complexity increases
Solution Approach 1:
The diagnostic approach is segmented into two distinct pathways: a simplified pathway using only the MS4A7 biomarker for initial screening and common cases, and a comprehensive pathway using multiple biomarkers (HP1BP3, TTC9B, MS4A7) for complex or atypical cases. This segmentation allows the system to achieve high diagnostic accuracy when needed while maintaining simplicity for routine diagnoses.
Solution Approach 2:
Different levels of diagnostic complexity are applied to different patient populations based on their specific needs. The patent implements local quality by making the diagnostic test complexity adaptive to the case complexity - simple tests for straightforward cases and comprehensive tests for complex cases, rather than applying uniform complexity to all diagnoses.
2Measurement precision
If multiple biomarkers are used for diagnosis, then diagnostic accuracy is improved, but time required for diagnosis increases
Solution Approach 1:
The diagnostic system is made dynamic by allowing the number of biomarkers analyzed to vary based on case complexity. The patent implements a flexible, adaptive diagnostic approach where the test panel size adjusts dynamically - starting with a single biomarker (MS4A7) for simple cases and expanding to multiple biomarkers (HP1BP3, TTC9B, MS4A7) only when clinical complexity warrants it, rather than always performing comprehensive testing.
Solution Approach 2:
The patent applies partial action by performing only the necessary level of testing required for each case. For most common PMDD cases, only the essential MS4A7 biomarker is tested, providing sufficient diagnostic accuracy without unnecessary additional time investment. Comprehensive multi-biomarker testing is reserved for atypical or complex cases where higher accuracy justifies the additional time required.
3Adaptability or versatility
If retrospective diagnosis is used for perimenopausal depression, then diagnostic flexibility is maintained, but treatment timing is delayed
Solution Approach 1:
The patent implements preliminary action by introducing DNA methylation biomarker testing that can detect perimenopausal depression during the perimenopausal transition period itself, before full-blown depression develops. This allows early identification and intervention during the window of opportunity when the perimenopausal brain is still plastic and responsive to treatment, rather than waiting for retrospective diagnosis after depression has fully manifested and potentially caused lasting damage.
Data Source
AI summary
The present invention relates to the field of Premenstrual dysphoric disorder (PMDD) and perimenopausal depression (PMD). More specifically, the present invention relates to the use of biomarkers to diagnose PMDD, PMD or predict a risk thereof. In one embodiment, a method for identifying a likelihood of PMDD and/or PMD in a patient comprises the steps of (a) providing a sample from the patient; (b) measuring white blood cell type counts and DNA methylation levels of a panel of biomarkers or using a proxy marker to estimate the ratio monocytesmon-monocytes in the sample collected from the patient, wherein the panel of biomarkers comprises HP1BP3 and TTC9B and the white blood cell type counts comprise monocytes and non-monocytes; and (c) using a linear model that utilizes the DNA methylation level of HP1BP3 and TTC9B and the ratio of monocytesmon-monocytes or proxy marker to determine the patient is likely to develop PMDD and/or PMD.